Research Paper Volume 11, Issue 15 pp 5445—5462

Figure 1. CRP promotes osteo-/chondrogenic transdifferentiation of HAoSMCs. (A) Scatter dot plots and arithmetic means ± SEM (n=8; arbitrary units, a.u.) of CBFA1 relative mRNA expression in HAoSMCs treated with control (CTR) or 10 µg/ml recombinant human CRP. (B) Representative original Western blots and scatter dot plots and arithmetic means ± SEM (n=10; a.u.) of normalized CBFA1/GAPDH protein ratio in HAoSMCs treated with control (CTR) or 10 µg/ml recombinant human CRP. (C) Scatter dot plots and arithmetic means ± SEM (n=8; a.u.) of ALPL relative mRNA expression in HAoSMCs treated with control (CTR) or 10 µg/ml recombinant human CRP. (D) Scatter dot plots and arithmetic means ± SEM (n=6, U/mg protein) of ALPL activity in HAoSMCs treated with control (CTR) or 10 µg/ml recombinant human CRP. (E) Representative original Western blots and scatter dot plots and arithmetic means ± SEM (n=10; a.u.) of normalized αSMA/GAPDH protein ratio in HAoSMCs treated with control (CTR) or 10 µg/ml recombinant human CRP. *(p<0.05), **(p<0.01) significant vs. control HAoSMCs.